Peptide Cancer Vaccine Market

Global Peptide Cancer Vaccine Market Size ( 2023 to 2028 )

The global peptide cancer vaccine market size is worth USD 4.65 Billion in 2023 and is anticipated to reach USD 9.62 Billion by 2028 with a CAGR of 10.58% in the forecast period.

Peptide vaccines are designed based on the epitope peptides, which elicit humoral and cellular immune responses by targeting tumor-specific antigens, which results in controlling or eradicating the tumor. The vaccine consists of amino acid sequences as tumor antigens where the vaccine adjuvant is attached. The peptide vaccine's enormous advantages make it successful as the peptide vaccine is easy to synthesize, cost-effective, and widely applied in clinical practice. The significant advantages of peptide cancer vaccine are low risk of anaphylaxis and flexibility in antigen changing. 

Market Drivers:

The rising prevalence of cancer and no progress in the traditional cancer treatment methods for eliminating and reoccurrence of the disease is expected to increase the demand for immunotherapy treatment methods such as the Peptide Cancer Vaccine. Cancer is the world's most significant disease where Cancer patients are predicted to reach around 19 million by 2024. The most common types of cancer are breast cancer, lung cancer, prostate cancer, and others. According to the International Agency for Research on Cancer, the number of cancer cases is projected to reach 29.5 million, and several cancer deaths reach 16.4 million. All these factors are enhancing the growth of peptide cancer vaccine adoption. The beneficial effects of peptide vaccines in other diseases by killing viruses such as hepatitis C, Coronavirus, and Influenza raise the demand for peptide vaccines. 

The growing technological advancements in the healthcare system in most developed countries, the progress of cancer medications, and rising government initiatives to bring awareness among the people regarding cancer are all factors boosting the growth of the peptide cancer vaccine market value. Effective cost and simple manufacturing and production techniques of peptide cancer vaccine are fueling the sales of peptide cancer vaccine. The ease of synthesizing, cost-effectiveness, ease of production, and clinical applications with lower risk of anaphylaxis and antigen-changing flexibility are primary factors influencing the growth of peptide cancer vaccine market revenue. All these factors are making the manufacturers focus on developing the efficiency of the peptide cancer vaccine by investing in research and development activities. 

The rising benefits of peptide cancer vaccines include easy synthesis methods with cost-effectiveness and significant clinical applications. All these factors are projected to have market growth opportunities over the forecast period. Increasing R&D activities due to growing investments by the market key players to provide highly effective cancer treatment. Synthetic peptide vaccines are stable, less allergic, and low autoimmune reactions are observed, which is expected to fuel the market growth. Low toxicity cases are highly influencing organizations to prefer peptide cancer vaccines, which is estimated to raise market revenue over the forecast period. 

Market Restraints:

The high cost of cancer treatment is expected to hamper the growth of the global peptide cancer vaccine market. Although peptide vaccines have various advantages, there are various disadvantages, such as false positives and negative responses, which are majorly restraining the adoption of peptide cancer vaccines. MHC restrictions are the major drawback of the peptide vaccine, where different T cells are restricted to either of the MHC class antigens. Few cases have shown inappropriate immunogenic epitope selection is expected to limit the market expansion. The peptide vaccines have poor immunogenicity, which requires adjuvants for functioning, and these are restricted to specific epitopes or antigens, which is expected to impede market growth.

The availability of various alternative treatment methods acts as competition for the peptide cancer vaccine market expansion worldwide. Professionals for cancer treatment are also adopting cancer vaccines like genetic, tumor, and dendritic cell vaccines due to their practical advantages compared to the peptide cancer vaccine market. 

COVID-19 Impact on the Peptide Cancer Vaccine Market:

The Pandemic had a substantial negative impact on the healthcare industry due to the sudden arrival of COVID-19. The Pandemic has affected the economies of various countries: pandemic lockdowns, transport restrictions, and business shutdowns. Only emergency cases are treated during the Pandemic and the spread of COVID. Manufacturing and distribution of peptide cancer vaccines had faced difficulties due to lockdown and transport restrictions. Disruption in the global supply, delivery, and sales of products are negatively impacted due to pandemic restrictions. Post-pandemic is expected to have a steady growth rate with increased market revenue. 

REPORT COVERAGE:

This research report on the peptide cancer vaccine market has been segmented and sub-segmented based on the type, application, and region.

Peptide Cancer Vaccine Market-By Type:

• Personalized Peptide Vaccine
• Peptide-Pulsed Dendritic Cancer Vaccine
• Peptide Cocktail Type
• Multivalent Peptide Vaccine
• Others

The multivalent peptide vaccine held the largest share of the global peptide cancer market revenue in 2022. These vaccines are gaining traction due to various benefits, such as their consisting of all essential epitopes, being immunogenic, and being able to be produced with low costs. Multivalent peptide vaccines are expected to provide robust immune protection, which helps fight the disease. All these benefits are driving the market growth in this segment. 

Personalized Peptide vaccine is projected to grow significantly over the forecast period with a prominent CAGR. Personalized peptide vaccines influence the T-cells depending on the pre-existing immunity of the host. The HLA-matched peptides are selected and administered based on the pre-existing immunity of the host before vaccination. Recent clinical trials on personalized peptide vaccines have shown clinical therapeutic approaches for various advanced cancers. 

Peptide Cancer Vaccine Market-By Application:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• Others

The Melanoma segment dominated the global market revenue with the most significant share in 2022 and is expected to dominate during the forecast period. Melanoma is a cancer disease that discolors the skin. The GP 100 peptide vaccine has been studied, undergone clinical trials, and has been approved for treating melanoma conditions. After vaccination, the T-cells recognize the cancer cells and kill them. 

The breast cancer segment is expected to grow significantly in the peptide cancer vaccine market over the forecast period. E75, GP2, and AE37 are the three single peptide vaccines for treating breast cancer. E75 AND GP2 consist of 9 amino acids in the epitope of HER2 protein. Breast cancer is prevalent across the world, and various studies show that the chance of an increase is expected to rise by 12% every year across the globe.

Peptide Cancer Vaccine Market-By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North American region held the largest share of the global market in 2022 and is expected to dominate during the forecast period. Various vital pharmaceuticals and biotech businesses in the region are fueling its market growth. Developed countries like the US and Canada have advanced healthcare systems and research institutions, influencing the adoption of peptide cancer vaccines for treatment. The government initiatives for educating the people regarding cancer and treatment options include implementing reimbursement policies for the treatment where these factors influence the market growth. The prevalence of cancer is high in the US, where, according to the American Cancer Society, there are 1.9 million new cases of cancer recorded in 2022, and over 609,360 cancer deaths were observed. 

Europe held second in the global peptide cancer market in 2022, with the most significant share due to the advanced healthcare system and high healthcare expenditure. Europe holds various critical pharmaceuticals and major cancer research centers that work on developing innovative methods of cancer treatment that influence market adoption. 

The Asia Pacific region is in third position in the market revenue share. It is expected to grow steadily over the forecast period due to increasing R&D activities to offer patients better and more efficient treatment. Various clinical trials are in progress regarding the peptide cancer vaccines, which are expected to impact the market revenue positively. Developed countries like China, Japan, and Australia are highly equipped with the advanced healthcare infrastructure and research institutes where peptide cancer vaccines are being the choice for cancer treatment.

KEY MARKET PLAYERS:

Enzo Life Science, Immatics Biotechnologies, Tapimmune, Merck, Sellas, Biolife Science, Vaxon Biotech, Lytix Biopharma, Isa Pharmaceuticals, and Oncotherapy Science are some of the key market players in the peptide cancer vaccine market.

RECENT MARKET DEVELOPMENTS:

• In September 2022, NEO-PV-01, a long peptide cancer vaccine, was launched by Neon Therapeutics. This vaccine, in combination with chemotherapy, is expected to work for melanoma, bladder cancer, and NSCLC. 
• In December 2021, in an educational session at ESMO, Immune-Oncology Congress, ISA Pharmaceuticals discussed critical learnings in cancer vaccine development.
• In September 2022, Immatics N.V. announced a preclinical data set for TCR Bispecific candidates targeting PRAME at the European Society for Medical Oncology Congress 2022.